UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-4785571 (State or other jurisdictio ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview NOVEMBER 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's belief ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2022 Results Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Ma ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview SEPTEMBER 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's belie ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2022 Results Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Joon ...

Intellia is Leading the Genome Editing Revolution Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Corporate Overview MAY 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ian Karp - SVP, IR & Corporate Communications John Leonard - President, CEO & Director David Lebwohl - EVP & Chief Medical Officer Laura Sepp-Lorenzino - EVP & Chief Scientific Officer Glenn Goddard - EVP, CFO & Treasurer Conference Call Participants Swapnil Malekar - Piper Sandler & Co. Maurice Raycroft - Jefferies Dae Gon Ha - Stifel, Nicolaus & Company Salveen Richter - Goldman Sachs Gro ...

Bill, living with transthyretin amyloidosis, and his wife, Maura ntellia Intellia is Leading the Genome Editing Revolution Corporate Overview MARCH 2022 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs a ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2021 Earnings Conference Call February 24, 2022 8:00 AM ET Company Participants Ian Karp ??? Senior Vice President-Investor Relations and Corporate Communications John Leonard ??? Chief Executive Officer Glenn Goddard ??? Chief Financial Officer David Lebwohl ??? Chief Medical Officer Laura Sepp-Lorenzino ??? Chief Scientific Officer Conference Call Participants Joon Lee ??? Truist Maury Raycroft ??? Jefferies Greco Song ??? SVB Leerink Swapnil Malekar ??? Piper ...

Bill, living with transthyretin amyloidosis, and his wife, Maura o real Corporate Overview November 2021 THERAPEUTIC 2 Intellia Therapeutics' Legal Disclaimer This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding our: abili ...